Loading patent…
AssigneeWuxi Shuangliang Biotechnology Co., Ltd.
InventorsPing Zhou, Jiaquan Wu, Shenshuang Jin, Li Li
Estimating the term…
Provided in the present disclosure are a pharmaceutically acceptable salt of an epidermal growth factor receptor (EGFR) inhibitor, a crystal form thereof, a preparation method therefor and an application thereof. The structural formula of the EGFR inhibitor is as shown in formula I, and the pharmaceutically acceptable salt is a mesylate, p-toluenesulfonate, phosphate, hydrochloride or citrate salt of the EGFR inhibitor. The pharmaceutically acceptable salt of EGFR inhibitor of the present disclosure has a specific crystal form, has a higher solubility and stability than a corresponding free base, is more suitable for preparing drugs for use in treating cancer (especially non-small cell lung cancer), and satisfies the requirements for bioavailability and drug efficacy.
A pharmaceutically acceptable salt of EGFR inhibitor, wherein the pharmaceutically acceptable salt is a salt formed by an EGFR inhibitor and an acid, the EGFR inhibitor has a structure represented by formula I,
An amorphous EGFR inhibitor phosphate salt, wherein the amorphous EGFR inhibitor phosphate salt is a salt formed by an EGFR inhibitor represented by formula I and phosphoric acid, and has the characteristic peaks of X-ray powder diffraction spectrum as shown in FIG. 7,
Dependencies are inferred from the claim text.